Purpose A retrospective comparison of the prevalence and diagnostic value of anti-Sa, anti-CEP-1, and anti-MCV autoantibodies relative to those of the established autoantibodies, composite RF and anti-CCP-IgG used routinely for RA diagnosis as a component of the ACR 2010 criteria, in a cohort of disease-modifying anti-rheumatic drug naïve African RA patients (n = 75). Methods Serum concentrations of anti-Sa, anti-CEP-1 and anti-MCV autoantibodies were measured using ELISA procedures, while anti-CCP-IgG antibodies were determined by fluorescence enzyme immunoassay, and composite RF by latexenhanced laser nephelometry. Results The seropositivity frequencies of anti-Sa, anti-CEP-1 and anti-MCV antibodies for the RA patients were 82, 72, 85%, respectively, while that of anti-CCP-IgG and RF was 87% for both. Overall, anti-MCV demonstrated the best specificity, positive predictive value (PPV), odds ratio and positive likelihood ratio of all the types of autoantibody tested. Conclusion These observations in this unique cohort of RA patients indicated novel associations of all three autoantibodies in regard to HLA-SE risk alleles, disease severity and tobacco use that were not reported before. Elevated anti-Sa titers designated a propensity of higher disease and high-risk alleles in our cohort. Anti-CEP-1 association with HLA-SE homozygosity and high-risk alleles is also novel in this group. Of note, measurement of anti-MCV antibodies on presentation, either as an adjunctive or even as a stand-alone test, surpassed all other biomarkers investigated here and, therefore, may add value to clinical management.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting the joints, leading to cartilage destruction and debilitating disease. Worldwide, RA affects 1-3% of the general population with females in the majority. Composite (IgA, IgG, IgM) rheumatoid factor (cRF) and anti-citrullinated peptide (anti-CCP-IgG) antibodies are components of the 2010 ACR/EULAR RA classification criteria, underscoring the serodiagnostic utility of these autoantibodies in RA [1] . The efficacy of this strategy in detecting early disease, thereby improving prognosis, is well-established worldwide [2] [3] [4] [5] , and includes black South African RA patients [5] [6] [7] [8] [9] . However, less is known about the diagnostic and prognostic potential of measurement of the more recently described autoantibodies, antiSa, anti-CEP-1 and anti-MCV in African patients with RA, as well as their associations with prominent disease risk factors, specifically tobacco usage and positivity for the human leucocyte antigen-shared epitope (HLA-SE).
The clinical utility of measurement of a group of anticitrullinated peptide antibodies (ACPAs), namely anti-Sa, anti-CEP-1 and anti-MCV autoantibodies, was evaluated in the current study. Serum levels and prevalence rates were compared with those of traditional anti-CCP-IgG and cRF autoantibodies in a cohort of disease-modifying, antirheumatic drug (DMARD)-naïve, black, predominantly female South African patients with RA. Furthermore, the sensitivities, specificities and normal threshold values of these ACPAs were also determined by inclusion of measurement in serum from healthy individuals and patients with systemic lupus erythematosus (SLE) or scleroderma.
Patients and methods
The study, which conformed to good clinical and laboratory practice and to the Helsinki Declaration, was approved by the Research Ethics Committees of the Faculties of Health Sciences of the Universities of the Witwatersrand and Pretoria.
The cohort consisted of a group (n = 75) of black African RA patients collected from 2010 that formed part of a previously described cohort, all diagnosed according to the 1987 ACR RA criteria and who were DMARD-naïve at baseline. All patients were started on methotrexate regimen with some on additional corticosteroids [6] . Methods for serological measurement of cRF and anti-CCPIgG have been described previously for this cohort of RA patients [6] [7] [8] . Sample aliquots were stored at -80 °C to prevent deterioration of antibodies. Controls (n = 75) consisted of 20 SLE patients, 26 scleroderma patients and 29 healthy individuals. Due to limited access to patients with other autoimmune diseases as well as budget consideration the control composition was composed as above to at least match the patient group. The fact that other autoimmune diseases known to react to these autoantibodies are not represented in the control group is a limitation and should be taken into consideration. We do, however, consider that the most common of autoimmune disorders in SLE and scleroderma is an advantage instead of normal healthy controls.
The standard classification for SDAI (Simplified Disease Activity Index) was used [remission = ≤ 3, low disease activity (LDA) = > 3 − ≤11, mild disease activity (MDA) = > 11 − ≤26, and high disease activity (HDA) > 26] [9] . DAS (Disease Activity Score) 28-3 scores were classified according to Fransen et al. [10] . Disease duration since onset of symptoms is expressed in months and was categorised as: (1) < 6 months (n = 24), (2) between 6 and 12 months (n = 27) and, (3) > 12 months (n = 24).
ELISA procedures were used to measure serum concentrations of anti-Sa (IU/ml) and anti-CEP-1(U/ml) (EUROIM-MUN AG, Luebeck, Germany), anti-MCV (U/ml) (Orgentec Diagnostika GmbH, Mainz, Germany), and cotinine (ng/ml) as a marker of tobacco usage (Calbiotech Inc., Spring Valley, CA, USA). Composite RF (IU/ml) and high sensitivity (hs)-CRP (mg/dl) were determined using latex-enhanced laser nephelometry (Siemens South Africa, Midrand, South Africa), while anti-CCP-IgG (EliA U/ml) was determined by fluorescence enzyme immunoassay (FEIA) using the automated Phadia 250 platform (Phadia AB, Uppsala, Sweden).
Both the molecular procedure used for HLA-DRB1 typing and categorisation of HLA-SE genotype have been described previously [7] . The HLA-SE classification was validated according to the RAA amino acid sequence at positions 72-74 of the third hypervariable region of the HLA-DRB1 gene and assigned SS or SX if both HLA-DRB1 alleles or only 1 allele expressed the RAA motif, respectively. Modulation of risk according to the types of amino acids at positions 70 and 71 of the third hypervariable region of the HLA-DRB1 gene enabled further subdivision into HLA-SE low-risk (LR) and high-risk (HR) alleles [11, 12] .
Statistical analysis
Descriptive and inferential statistics techniques were used in the analyses. Tests for association of contingency tables were performed using two-tailed chi-squared or Fisher's exact tests. One-way ANOVA, and both paired and unpaired t tests were performed after skewed data were log transformed. Correlation coefficients were derived from correlation matrices using Bonferroni's method p value correction for multiple testing. The empirical estimation of cut-off points for diagnostic tests was performed using Phil Clayton's (ANZDATA Registry, Australia) STATA program 'cutpt' which is based on ROC (receiver operator curve) analysis. We used 'cutpt' with the Liu method which maximises the product of the sensitivity and specificity. The estimated cut-off point returned was bootstrapped to estimate confidence intervals. Statistical significance was determined at a p value < 0.05 and confidence intervals of 95%. The analyses were performed using STATA 13, Statacorp, Texas, USA.
Results

Demographics
The demographics and HLA-SE related data of the group of RA patients are summarised in Table 1 . The median group age was 48 years, with a median SDAI score of 40, DAS28-3 of 5.5 and disease duration of 9 months. Eightyone percent were female, and 25% used tobacco products. Of the control groups, the SLE and scleroderma groups were age and gender compatible with median ages recorded of 43 and 45 years, respectively, and predominantly female. The healthy group was age match (median age 46) but with a gender ratio of 2:1 (19 female:11 males). Seropositivity rates of the different test autoantibodies for patients and control groups as shown in Table 2 . Anti-MCV had the lowest positivity rate in the control group, whilst anti-CEP-1 was the highest number of false positives in the control groups. Although our cohort presented with a low number of seronegative RF patients, n = 10 (13%), the frequency of seropositivity for the three test ACPAs was around 50% (anti-San = 5/10, anti-CEP-1-n = 6/10 and anti-MCV-n = 5/10), which was comparable to CCP positivity (n = 6/10).
Validation of cut-off values
The cut-off values of the various test autoantibodies recommended in the product inserts were evaluated according to ROC (receiver operating characteristic) analysis, based on results obtained from RA patients, relative to those of healthy control subjects and patients with SLE or scleroderma.
Plot analysis of ROC curves showed that anti-MCV had a AUC ( (empirical optimal cut-off) was calculated as 91 for anti-MCV with a sensitivity 0.86 and specificity of 0.98 at cutoff. For anti-CEP-1 EOC was 46 with a sensitivity of 0.72 and specificity of 0.79 at cut-off. Anti-Sa and anti-CCP-IgG EOC matched the commercially suggested cut-offs of 10, with a sensitivity of 0.86 and 0.87 as well as a specificity of 0.89 and 0.86 at cut-offs for anti-Sa and anti-CCP-IgG, respectively. Anti-CCP-IgG and anti-Sa cut-offs concurred with those of the suppliers, while the recommended commercial cut-off values for anti-CEP-1 and anti-MCV were adjusted to 46 RU/ml and 91 U/ml, respectively, and applied to determine further indicators as discussed below and shown in Table 3 .
The sensitivities, specificities, positive predictive values (PPVs), negative predictive values (NPVs), odds ratios and positive (+), negative (−) likelihood ratios (+LR, −LR) for cRF, anti-CCP-IgG, anti-Sa, anti-CEP-1 and anti-MCV are shown in Table 3 and demonstrate that cRF and anti-CCPIgG are the most sensitive with respect to prediction of RA. Anti-MCV had the best overall specificity and PPV (> 95%) of all autoantibodies tested, as well as the highest +LR value of 260 compared to 9.3 and 6.3 for cRF and anti-CCP-IgG, respectively.
A matrix correlation between the citrullinated autoantibody titres indicated that anti-CCP-IgG values showed good correlations with anti-MCV and anti-CEP-1 (rho = 0.712, p < 0.000 and rho = 0.390, p = 0.003, respectively). Anti-MCV and anti-CEP-1 were also significantly inter-correlated (rho = 0.374, p = 0.006).
Disease severity indicators
DAS28-3 and SDAI scores DAS28-3(CRP) and SDAI scores at first presentation were used as indicators of disease severity. Baseline DAS28-3 scores revealed that 6 (8%), 27(36%) and 42 (56%) of RA patients had inactive, moderately active and very active disease, respectively. SDAI at baseline indicated that 25% (n = 19) and 75% (n = 56) of patients, respectively, had HDA, while no patients had LDA or were in remission. DAS28-3 and SDAI scores showed a very significant correlation (rho = 0.866, p < 0.000). In addition, the classification categories of the two different clinical scoring systems were highly compatible according to Fishers' Exact test (p > 0.000).
None of the three citrullinated autoantibody titres under investigation showed statistical significant correlations with the classic disease markers, DAS28-3, SDAI and disease duration individually. However, when combined RF and anti-CCP-IgG positivity was introduced as an additional contributory factor, anti-Sa titers were significantly elevated for DAS28-3 (p = 0.039), SDAI (p = 0.019) and disease duration (p = 0.024), (Table 4) . Furthermore, baseline anti-Sa titres were the highest in the setting of disease duration of 6 months or less when compared with the corresponding median values at 6-12 months disease duration (p = 0.010) or longer (p = 0.024) as shown in Fig. 1 .
Anti-CEP-1 positivity significantly, albeit weakly, correlate with the SDAI classification (p = 0.046); in this context, 81% (n = 43) of the patients classified with HDA had elevated levels of anti-CEP-1.
Risk factors
HLA-SE Seventy-one (95%) RA patients had an HLA-SE allele, of which 30 (40%) were heterozygous (SX), i.e. had a single HLA-SE-associated allele, and 55% where homozygous (SS) for HLA-SE. Only four (5%) of the patients expressed no HLA-SE phenotype (XX) ( Table 1) . Further classification according to the SE sequence and modulation thereof by amino acid sequences of the HLA-DRB1 gene Comparing the HR vs. LR groups revealed that only median anti-Sa titres were significantly higher (p = 0.012) in the HR group compared to the LR group. Anti-CEP-1 bordered on statistical significance (p = 0.052) and anti-CCPIgG (p = 0.074) showed the same trend as shown in Fig. 3 .
Tobacco use Tobacco use, according to serum cotinine levels in excess of 3.0 ng/ml [13] , was detected in 34 (45%) Fig. 1 Effect of therapy on serum levels of anti-Sa autoantibodies, demonstrating higher titers on presentation which decline significantly on therapy Response to treatment SDAI response The response to treatment was determined as a percentage increase/decrease in SDAI when baseline scores were compared to SDAI scores at 6 months. Categories were defined from the original suggested SDAI response categories (SDAI 50, 70, 85% or minor, moderate and major responses) [14] . Of 67 patients for whom both baseline and 6 months SDAI scores were recorded, 30 (44.8%) patients did not achieve a minor change (< 50%), 17 (28.4%) attained a minor (50-70%), 10 (14.9%) a moderate (70-85%) and 10 (14.9%) a major response (> 85%). SDAI responses were further classified as binary, with either no response (< 50%) or any response (> 50%), according to which 30 (44.8%) patients showed no response vs. 37 (55.2%) who had a response.
Comparison of the titres of the different citrullinated autoantibodies in relation to the SDAI categorical response using the Kruskal-Wallis test revealed a statistically significant association of anti-MCV titres with SDAI (p = 0.031), while the SDAI binary response classification indicated that elevated titres of anti-CCP-IgG (p = 0.027) and anti-MCV (p = 0.003) antibodies at presentation were associated with the SDAI response. These associations, particularly in the case of anti-CCP-IgG, were strongest in the case of tobacco users, the levels of statistical significance being p = 0.007 and p = 0.002 for anti-CCP-IgG and anti-MCV antibodies respectively. Similar associations were not, however, detected in the case of non-tobacco users (p = 0.413 and p = 0.129 for anti-CCP-IgG and anti-MCV, respectively).
Discussion
The serodiagnostic utility of inclusion of ACPAs other than CCP either individually or as an adjunctive strategy to enhance the diagnostic value of measurement of RF and/ or CCP has been described in several studies [15] [16] [17] [18] [19] , most importantly in seronegative RA [20] [21] [22] [23] . The findings of these studies are supported and extended by those of the current study.
In the current study, elevated levels of anti-Sa showed an association with higher disease activity as previously reported [24, 25] , as well as with HLA-SE homozygosity and high-risk alleles. Interestingly, this finding of an association of anti-Sa autoantibodies with genetic predisposition and high risk have not, to our knowledge, been previously described, possibly justifying the inclusion of anti-Sa in the profile of serodiagnostic tests for our RA population. In this context, it is noteworthy that anti-Sa is directed against citrullinated vimentin [26] which has been shown in both murine experimental models and in humans with RA to bind to HLA-DRB1*0401 [27] .
Associations of anti-CEP-1 antibodies with disease severity and HLA-SE, as well as with smoking, have been reported previously, mostly in RA patients of Caucasian origin [28] [29] [30] and, according to the findings of the current study, these associations are also evident in RA patients of African origin. The association with HLA-SE motif is underscored not only in the case of RA patients who present as homozygous for the HLA-SE genotype, but also those with high-risk alleles, an observation, which, to our knowledge, has not been described previously.
In the case of anti-MCV, measurement of this autoantibody demonstrated impressive specificity, positive predictive value and a positive likelihood ratio, as well as significant associations with SDAI response especially with tobacco use, indicative of its potential to act as the preferred RA serodiagnostic procedure in our setting. Although the diagnostic potential of anti-MCV, as well as its role in the immunopathogenesis of RA, are well-described [31, 32] , as are its associations with other ACPAs, HLA-SE and smoking [19, [33] [34] [35] , measurement of this autoantibody in the cohort of RA patients described in the current study appears to be of particular diagnostic value, exceeding the predictive odds ratio of any other ACPA test by fourfold. However, this finding has to be tempered by a consideration of the adjusted cut-off value, warranting further testing with larger cohorts.
In conclusion, measurement of anti-Sa as an additional biomarker in the routine serodiagnosis/prognosis of RA may have added value, albeit limited, in the context of assessment of disease severity. Most importantly, however, anti-MCV is shown to be equivalent to, possibly even exceeding, the serodiagnostic potential of any of the other autoantibodies tested in the cohort of South African patients investigated in this study.
Funding This study was funded by departmental funds of the Rheumatology and Immunology Departments involved, no grant funds were used.
Compliance with ethical standards
Conflict of interest None of the authors have any conflict of interest to disclose. Informed consent Informed and signed consent was obtained from each individual participant included in this study as per the institutions Ethics Boards requirement.
Ethical approval
